AUCextrap more than 20% [Study As­sess­ment]

posted by ElMaestro  – Denmark, 2013-08-01 12:29 (4717 d 14:18 ago) – Posting: # 11139
Views: 31,110

Hi Sam,

❝ (...) the study fails marginally in lower CI in AUCt that is 79.28. The failure in this study is due to the presence of two outlier in the whole study. If we remove these outliers the study qualify the BE criteria for all the three parameters. But as we all know that USFDA don’t encourage the outliers test and its exclusion from the study (...) So please suggest if we can do in same line as I am thinking or there are any other ways to save our study.


If you can for-cause audit the study and ID justifiable reasons for exclusion of the subjects in question then that would most likely be ok (pukey-pukey in period 1 but not in period 2 and stuff like that). But it takes real effort to do it, and the audit should not just focus on the values/subjects that you believe caused study failure but also on the subjects that were in your views within the normal range.

A little off topic, but given the recent discuss in another thread, this example is one where the concept of a repeat trial may become relevant. If your lower CI limit was 79.28% then chances are that the true T/R (geometric mean, observed) was likely to be reasonably close to 100% and that more subjects in the trial therefore would have saved it. Got some numbers for us?

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
230 visitors (0 registered, 230 guests [including 31 identified bots]).
Forum time: 02:47 CEST (Europe/Vienna)

When you meet the Buddha, you kill him;
when you meet the patriarchs, you kill them.    Wumen Huikai

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5